Balancing the uncertainties of exposure and hazard

The extent of accommodation and characterization of uncertainty in exposure assessment must necessarily be balanced against similar considerations with respect to hazard, since the outcome of any risk assessment is a function of comparison of the two. If, for example, there is limited information to inform quantitatively on hazard and, as a result, a need to rely on defaults, there is limited benefit to be gained in developing the exposure analysis such that any increase in certainty is cancelled by uncertainties of greater magnitude associated with quantification of critical hazard, as a basis for a complete risk assessment. 

estimates of exposure are compared directly with benchmark doses or concentrations (i.e. those that result in a critical effect of defined increase in incidence, such as 5% or 10%). Alternatively, they are compared with either a lowest-observed-adverse-effect level (LOAEL), the lowest concentration that leads to an adverse effect, or no-observed-adverse-effect level (NOAEL), the highest concentration that does not lead to an adverse effect, or their equivalents. This results in a margin of safety or margin of exposure . Alternatively, estimates of exposure are compared with tolerable or reference concentrations or doses, which are based on the division of benchmark doses and/or concentrations or the NOAELs or LOAELs by factors that account for uncertainties in the available data. 

The NOAEL or benchmark dose/concentration is selected, then, generally to be at or below the threshold in animals uncertainty factors are then applied to estimate the subthreshold in sensitive human populations, with a 10-fold default factor addressing interspecies differences (i.e. the variation in response between animals and a representative healthy human population) and another 10-fold factor accounting for interindividual variability in humans (the variation in response between a representative healthy human population and sensitive subgroups). While additional factors are sometimes applied to account for deficiencies of the database, the 100-fold default value is common. 

Division of benchmark doses and/or effect levels by default uncertainty factors represents the lower end of a continuum of increasingly data-informed approaches to estimation of hazard. For example, where additional adequate quantitative data on interspecies differences or human variability in either toxicokinetics or toxicodynamics (mode of action) are available, chemical-specific adjustment factors provide for their incorporation to replace appropriately weighted components of default uncertainty factors. This requires subdivision of default 

Physiologically based pharmacokinetic (PBPK) modelling sometimes constitutes a basis for replacement of default components of uncertainty for toxicokinetics and a portion of toxicodynamics. Where data are sufficient, a full biologically based dose-response model addresses additional uncertainties with respect to both interspecies differences and interindividual variability in both kinetics and dynamics. 

---